Andrew Lamb's blog

Andrew Lamb's picture

Word on the Tweet: Listening to the Diabetes Community on Twitter


As a healthcare digital strategist, when I want to [[wysiwyg_imageupload:151:]]
understand trends and get a sense of what online communities are saying, Twitter is an essential source of data. The healthcare arena has generally been slow at adopting social media (mainly for regulatory reasons) but this is changing.

To demonstrate this, we developed the infographic at the bottom of this post to analyze Twitter activity from the diabetes community around EASD 2012, the European Association for the Study of Diabetes’ 2012 congress held in Berlin.

The infographic provides insight on a number of questions. Which stories dominated conversation at EASD 2012? Who were the main contributors? Was the diabetes patient community part of the discussion? How active were pharmaceutical companies at communicating on Twitter? It underlines the fact that those involved in the communication of science are rapidly adapting to a world where news moves faster and reaches more people, and where old boundaries, such as those between scientists and the public, are becoming more fluid. Read full post »

Andrew Lamb's picture

A European Perspective on Social Media and the FDA’s New Guidance

1 comment

While it falls short of the comprehensive guidance [[wysiwyg_imageupload:115:]]
on social media that many were hoping for, the FDA’s new document on responding to unsolicited requests does have an interest and relevance for those working in healthcare communications on the other side of the Atlantic.

Of course, no digital project is completely ‘local’ and Europeans should always have half an eye on developments elsewhere in the world. More importantly though, the FDA has given us a useful clue to what regulators are thinking and the issues they face in coming up with clear rules for the rapidly evolving environment of the web and social media. It could also set the tone for European guidance, if and when it appears.

The most significant aspect of the FDA’s new document is that: Read full post »

In: Digital & Social Media  /   filed under: EU | FDA | pharma | Social Media | UK